Belharra Therapeutics
Latest round
- Series A
Last raised
- Jan 2023
Total raised
- $130M
Investors
- 2
About Belharra Therapeutics
Based in California, US, and founded in 2021 by Christopher G. Parker, John Teijaro, Benjamin Cravatt, and Stuart Schreiber, Belharra Therapeutics operates as a drug discovery platform that develops novel drugs and therapies for difficult-to-treat diseases. In January 2023, Belharra Therapeutics, Inc. and Versant Ventures. The firm’s partners include Scripps Research and Genentech. The company operates a chemoproteomic-based drug discovery platform that identifies functional and actionable non-covalent, small molecule drug candidates for any binding site, on any protein, in any conformational state, and in any cell type. The platform allows screens to be run in a whole cell context, allowing the small molecule library to interact with proteins in their native conformations, including protein complexes, to create and identify therapeutics for previously difficult-to-treat conditions.
Who invested in Belharra Therapeutics
2 investors across 1 round
See all investors in Belharra Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 4, 2023
Amount
$130M
Investors
Questions about Belharra Therapeutics
Who invested in Belharra Therapeutics?
Belharra Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Belharra Therapeutics raised?
Belharra Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Belharra Therapeutics last raise money?
Belharra Therapeutics's most recent round on record is a Series A, in Jan 2023.
What does Belharra Therapeutics do?
Based in California, US, and founded in 2021 by Christopher G.
Where is Belharra Therapeutics headquartered?
Belharra Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like Belharra Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Belharra Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Belharra Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.